Dec. 6 (Bloomberg) -- Roche Holding AG’s experimental schizophrenia medicine RG1678 reduced symptoms, and a new treatment for a kind of blood cancer “showed promising response rates,” mid-stage studies found.
The schizophrenia drug was also linked to beneficial changes in patients’ personal and social functioning, the Basel-based company said today in a statement.
As many as 55 percent of patients responded to treatment with the experimental compound GA101, which is being tested for use in people with difficult-to-treat Non-Hodgkin’s lymphoma who have failed multiple previous treatments, the company said in a another statement. Roche gained GA101 through its 235-million Swiss franc ($241 million) acquisition in 2005 of Switzerland’s GlycArt. Both RG1678 and GA101 are in the second of three stages of clinical development generally needed to win regulatory approval.
To contact the reporter on this story: Carey Sargent at email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org